Compare Raytheon Technologies Corp (RTX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Raytheon Technologies Corp trades at $184.79 (market cap $248.42B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.11B). The key difference: Raytheon Technologies Corp is far larger — about 24.6× State Street SPDR S&P Biotech ETF's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 78 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| RTX | XBI | |
|---|---|---|
Market Cap | $248.42B | $10.11B |
Volume | 4,380,368 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $225.49 | $169.55 |
52-Week Low | $157.00 | $104.99 |
Typical Hold Time | 78 Days | 37 Days |
Enterprise Value | $278.97B | — |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
